Page 14 - Read Online

Page 8 of 9 Gauduchon et al. J Cancer Metastasis Treat 2019;5:72 I http://dx.doi.org/10.20517/2394-4722.2019.023

DECLARATIONS
Authors’ contributions
Wrote and reviewed the manuscript: Gauduchon T, Reverdy T, Gau M, Karabajakian A, Collet L, Neidhardt
EM, Fayette J

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394‑424.
2. Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, et al. Chemotherapy for recurrent/metastatic head and neck
cancers. Anticancer Drugs 2017;28:357‑61.
3. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, et al. Nivolumab vs investigator’s choice in recurrent or metastatic
squamous cell carcinoma of the head and neck: 2‑year long‑term survival update of CheckMate 141 with analyses by tumor PD‑L1
expression. Oral Oncol 2018;81:45‑51.
4. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for
recurrent or metastatic head‑and‑neck squamous cell carcinoma (KEYNOTE‑040): a randomised, open‑label, phase 3 study. Lancet
2019;393:156‑67.
5. Ferris RL, Even C, Haddad R, Tahara M, Goswami T, et al. Phase III, randomized, open‑label study of durvalumab (MEDI4736)
monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell
carcinoma of the head and neck (SCCHN): eagle. J Immunother Cancer 2015;3:P150.
6. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, et al. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for
recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Available from: https://oncologypro.esmo.org/Meeting‑
Resources/ESMO-2018-Congress/KEYNOTE-048-Phase-3-study-of-first-line-pembrolizumab-P-for-recurrent-metastatic-head-and-
neck‑squamous‑cell‑carcinoma‑R‑M‑HNSCC. [Accessed on 23 Oct 2019]
7. Sun XS, Sire C, Tao Y, Martin L, Alfonsi M, et al. A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with
radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): first results of the GORTEC
2015‑01 “PembroRad” trial. J Clin Oncol 2018;36:6018.
8. Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, et al. Neoadjuvant pembrolizumab in surgically resectable, locally
advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2017;35:6012.
9. Ferris RL, Gonçalves A, Baxi SS, Martens U, Gauthier H, et al. LBA46An open‑label, multicohort, phase 1/2 study in patients with
virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and
neck (SCCHN). Ann Oncol 2017;28.
10. Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial
immunotherapy approaches. ESMO Open 2016;1:e000122.
11. Cho BC, Daste A, Ravaud A, Salas S, Isambert N, et al. 1048OM7824 (MSB0011359C), a bifunctional fusion protein targeting PD‑L1
and TGF-β, in patients (pts) with advanced SCCHN: results from a phase I cohort. Ann Oncol 2018;29.
12. André P, Denis C, Soulas C, Bourbon‑Caillet C, Lopez J, et al. Anti‑NKG2A mAb is a Checkpoint Inhibitor that Promotes Anti‑tumor